[Acute hepatitis of unspecified etiology: etiological structure and clinical-laboratory characteristics].

The straight line nucleic acids detection method of viruses and wide spectrum of virus antigens immunodiagnostics in acute hepatitis of unknown etiology patients has allowed verifying the diagnosis at 19% cases (a viral hepatitis A, C or E). Results of research do not allow to consider hepatotropic viruses HGV, TTV, PV B19, EBV, CMV, HHV 1, 2, 6 and 8 type, NV-F as etiological agents at the majority of patients of investigated group, and the data of the anamnesis and a clinical and laboratory picture of a current of disease does not allow to exclude at 29.4% of patients a drug-induced hepatitis. Despite detailed molecular-biological and immunological inspection of patients, at 37.9% of acute hepatitis of unknown etiology patients it was not possible to establish a connection with hepatitis and defined etiological factor (the infectious agent).

[Blood levels of HbsAg in patients with different variants of chronic HBV-infection].

AIM: To estimate HbsAg in patients with different variants of chronic HBV infection. MATERIAL AND METHODS: Assay of HbsAg (IU/ml) in blood serum was made in 156 patients with chronic HBV infection (70 males and 86 females, age 19 to 78 years) using the test-system HbsAg Architect Lot 59665LF00 (Abbott) on the automatic analyzer Architect with construction of 4-parameter logistic curve. RESULTS: There are significant differences in the levels of HbsAg depending on the course of chronic HBV-infection: inactive carriers of HBV (12,884.14 +/- 5,512.26 IU/ml) had much lower blood levels of HbsAg than patients with HbeAg-negative (66,992.28 +/- 25,908.74 IU/ml) and HbeAg-positive chronic VHB (135,039.3 +/- 48,127.06 IU/ml) patients with chronic mixed hepatitis (82,783.12 +/- 21,001.34 IU/ml) and cirrhosis of HBV-etiology (67,477.86 +/- 24,081.9 IU/ml). No significant differences were found between two subgroups of pregnant women with or without viremia by HbsAg concentration in the blood. Maximal mean content of blood HbsAg was registered in patients with HbeAg-positive chronic hepatitis B. CONCLUSION: Significant differences in blood serum levels of HbsAg exist between patients with chronic viral hepatitis B and inactive carriers of HBV.

[Immune status of patients with different outcomes of acute hepatitis C].

AIM: To ascertain parameters of immune response significant for prognosis of the disease outcome in patients with acute hepatitis C (AHC). MATERIAL AND METHODS: Seventy two examinees were divided into three groups: 30 patients of group 1 had AHC; 29 patients of group 2 had chronic hepatitis C (CHC) with the disease history 3-10 years; 13 AHC convalescents who had the disease 3-10 years ago. The control group consisted of 10 healthy subjects. The following parameters of immune status were studied: CD3+, CD4+, CD8+, CD16+, CD20+, HLA-DR+CD3+, CD95+, O-lymphocytes. RESULTS: By clinicobiochemical picture and the results of 12-month follow-up RT-PCR investigations of blood HCV RNA, AHC patients were divided into two groups: in 18 (72%) of 25 patients AHC became chronic, 7 (28%) patients achieved convalescence. The proportion and absolute number of subpopulations of lymphocytes CD8+, CD20+, CD16+ as well as CD4/CD8 in patients with AHC with different outcomes did not differ from the controls. AHC convalescents and patients with AHC transformation into chronic hepatitis had in the acute period of the disease much higher absolute number of subpopulations of the lymphocytes CD3+, CD4+, HLA-DR+CD3+ vs the controls. In patients with chronic hepatitis C with elevated levels of AlAT, 3-10 year follow-up registered significantly higher absolute amount of CD8+, CD3+, CD4+, HLA-DR+CD3+ vs the controls. Only patients with AHC which later became chronic had for 6 months of the disease significantly elevated absolute number of O-lymphocytes vs the controls. CONCLUSION: A high absolute count of O-lymphocytes in AHC patients may indicate probable development of chronic hepatitis C.

[Clinical and laboratory evaluation of efficiency and tolerance of the "Nikavir" in acute hepatitis B]. / Kliniko-laboratornaia otsenka terapevticheskoi éffectivnosti i perenosimosti protivovirusnogo preparata "Nikavir" pri ostrom gepatite B.

New antiviral drug "Nikavir" was clinically tested in acute hepatitis B (AHB). A total of 60 AHB patients were followed up; 30 patients were in the main group and 30 persons were in the control group. The treatment with Nikavir of AHB patients was shown to ensure a favorable clinical disease course and it was accompanied by a quicker rate in reduction of the activity of serum enzymes AIAT, AcAT, alkaline phosphatase and of gamma-glutamil-transpeptidase; besides, it was accompanied by an early elimination of such serum markers of AHB like HBeAg, HbsAg and HBV DNA. Wikavir can be used in the treatment of patients with mild and moderate forms of AHB.

[The role of hepatitis C virus RNA detection in various substrates of patients with chronic hepatitis C]. / Znachenie viiavleniia RNK virusa gepatita C v razlichnykh substratakh u bol'nykh khronicheskim gepatitom C.

Puncture biopsy of the liver and blood count were made in 72 patients with chronic hepatitis C (CHC). Morphological alterations in the liver were assessed by Knodell index. The blood serum, lymphocytes and hepatic tissue were examined for a genome form of hepatitis C virus (HCV) RNA, blood lymphocytes and hepatic tissue--for a relevant replication form. HCV RNA was detected using "nested" RT-PCR. Only 26% patients had symptoms of asthenovegetative and dyspeptic syndromes. Normal alaninaminotransferase (ALT) level was observed in 24% patients, the rest had it high. HCV RNA was encounted more frequently in hepatic tissue than lymphocytes or serum (83, 68 and 46%, respectively). A replication form of HCV RNA was present in hepatic tissue of 31% patients and was absent in the lymphocytes. The incidence of the RNA detection was not related either to the disease symptoms or morphological alterations in hepatic tissue. The occurrence of the genome and replication forms in hepatic tissue does not correlate to ALT level. HCV RNA occurs more often in the serum, blood lymphocytes and in three substrates simultaneously in patients with hyperalatemia.